Exbio — Research products — Antibodies — Nucleus — Anti-Hu p53 (pS392) Purified

Anti-Hu p53 (pS392) Purified

Regulatory status

RUO

Antigen

p53 (pS392)

Clone

FP3.2 [FPS392]

Format

Purified

Reactivity

Human

Application

WB, IHC(P)

Variant

0.1 mg

11-467-C100

In stock

198.00 USD

0.025 mg

11-467-C025

In stock

99.00 USD

Variant

0.1 mg

11-467-C100

In stock

198.00 USD

0.025 mg

11-467-C025

In stock

99.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody FP3.2 [FPS392] reacts with human p53 tumour suppressor intracellular protein phosphorylated at CKII site (Ser 392).

Application

WB, IHC(P)

Application details

Immunohistochemistry (paraffin sections): Standard ABC technique (DAB+), pretreatment: high temperature antigen retrieval (microwave, pressure cooker) in 10 mM citrate buffer pH 6.0 or 1 mM EDTA-NaOH buffer pH 8.0, recommended dilution: 10 μg/ml, incubation: 1 hour at RT; or overnight at 4°C, positive tissue: breast carcinoma with high level of wild-type p53.
Western blotting: recommended dilution: 1 μg/ml.

Reactivity

Human

Immunogen

KLH-conjugated phosphopeptide RHKKLMFKTEGPDS[P]D, corresponding to amino acids 378-393 of human p53.

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

BCC7, TRP53, TP53, LFS1

Antigen description

The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.

Entrez Gene ID 7157

UniProt ID P04637

Immunohistochemistry staining of Wild-type p53 expressed in human trophoblast (paraffin-embedded sections). A – anti-p53 (total) B – anti-p53 (phospho Ser392) Note that some of total p53 positive nuclei are also FP3.2 (phospho p53) positive.

Western blotting analysis of phosphorylated human p53 using mouse monoclonal antibody FP3.2 (purified) in T47D cell line, which expresses p53. A) Phosphorylated p53 detected in T47D cell line. B) Absence of phosphorylated signal of p53 in dephosphorylated T47 cells (pretreated with calf intestinal alkaline phosphatase).

General references:

Tanigawa S, Fujii M, Hou DX: Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem. 2008 Mar;72(3):797-804.
PubMed

Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR: p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene. 1999 Jan 14;18(2):283-95.
PubMed

Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS, Stark GR: Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell. 1999 Nov;10(11):3607-22.
PubMed

Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR: A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14775-80.
PubMed

Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8493-7.
PubMed

Product specific references:

Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, Hupp TR: Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene. 2000 Aug 10;19(34):3829-39.
PubMed

Sikorski K, Mehta A, Inngjerdingen M, Thakor F, Kling S, Kalina T, Nyman TA, Stensland ME, Zhou W, de Souza GA, Holden L, Stuchly J, Templin M, Lund-Johansen F: A high-throughput pipeline for validation of antibodies. Nat Methods. 2018 Nov;15(11):909-912.
PubMed

Koutová D, Havelek R, Peterová E, Muthná D, Královec K, Breiterová K, Cahlíková L, Řezáčová M: Pancracine, a montanine-type amaryllidaceae alkaloid, inhibits proliferation of A549 lung adenocarcinoma cells and induces apoptotic cell death in MOLT-4 leukemic cells. Int J Mol Sci. 2021 Jun 29;22(13):7014.
PubMed